API | filibuvir

filibuvir Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Filibuvir was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy. It was intended to be taken twice-daily. ^Wikipedia

Chemistry

SMILES: CCc1cc(CC[C@]2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1
InChIKey: SLVAPEZTBDBAPI-GDLZYMKVSA-N
Mol. Mass: 503.65
ALogP: 5.12 Partition coefficient
ChEMBL Molecule:
filibuvir

More Chemistry

Pharmacology

Mechanisms of Action:
- RNA-directed RNA polymerase (Hepatitis C virus) ^UniProt
- RNA-directed RNA polymerase (Hepatitis C virus genotype 1) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-(1,2,4)triazolo(1,5-a)pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one | filibuvir | pf00868554 | pf 00868554 | pf-00868554 | pf868554 | pf 868554 | pf-868554

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Healthy Volunteers (Phase 1)

Hepacivirus (Phase 1)

Hepatitis (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 1)

Hepatitis, Chronic (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue